查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2141423

數位糖尿病管理市場機會、成長要素、產業趨勢分析及2026-2035年預測

Digital Diabetes Management Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 200 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球數位糖尿病管理市場預計到 2025 年將達到 202 億美元，年複合成長率為 13.3%，到 2035 年將達到 691 億美元。

市場範圍
開始年份 2025
預測期 2026-2035
上市時的市場規模 202億美元
預計金額 691億美元
複合年成長率 13.3%

市場成長的驅動力在於糖尿病診療模式的重大轉變，即從間歇性的臨床諮詢轉向由整合數位生態系統支援的、技術驅動的持續監測。人口老化、久坐的生活方式和不斷上升的肥胖率導致糖尿病盛行率持續攀升，全球患者群體顯著擴大。同時，醫療系統面臨著病患需求與內分泌專科醫生供給之間日益擴大的差距，這加速了數位化自我管理工具的普及。在一些發展中地區，專科諮詢資源的匱乏進一步加劇了對遠距監測平台和遠端醫療解決方案的依賴。與糖尿病相關的醫療成本不斷上漲也促進了數位化醫療技術的潛在市場擴張。近年來，人們對持續血糖監測、互聯胰島素輸注系統和整合數位健康平台的認知度和應用率顯著提高。這一趨勢得益於更嚴格的臨床指南、不斷擴大的保險報銷範圍以及越來越多的證據表明，數位化介入能夠改善患者的治療效果。總體而言，隨著醫療保健向互聯、主動和數據驅動的糖尿病管理模式轉變，市場正在快速發展。

預計到2025年，持續血糖監測系統市佔率將達到53.4%，並在2035年之前以13.3%的複合年成長率成長。由於能夠提供即時血糖值追蹤和連續代謝訊息，該類別仍然是市場的核心支柱。與僅提供間歇性測量的傳統監測方法不同，這些系統提供連續的資料流，有助於預測性警報、模式識別和改善胰島素劑量決策。在改善血糖控制和減少併發症的臨床療效持續推動其在患者群體中的普及。

醫院領域是成長最快的終端用戶領域，預計到2025年將佔全球數位糖尿病管理市場收入的62.9%，並在預測期內維持13.7%的複合年成長率。這一成長主要得益於以下因素：患者照護持續血糖監測（CGM）投入的增加、糖尿病專科治療部門對自動胰島素輸注（AID）技術的日益普及，以及用於臨床分析、患者群體監測和報告的企業級數據管理平台的廣泛應用。隨著臨床研究不斷證實CGM系統能夠改善住院患者照護各環節的血糖控制，其在醫院環境中的應用正迅速發展。

預計到2025年，北美數位糖尿病管理市場將佔據33.4%的市場佔有率，並在2035年之前以13.1%的複合年成長率成長。由於完善的醫療保健基礎設施、數位健康技術的高普及率以及有利的報銷機制，該地區仍然是最先進、商業性化程度最高的市場。加拿大也呈現穩定成長的態勢，這主要得益於主要省份公共醫療保險對先進血糖監測解決方案的覆蓋範圍不斷擴大。此外，隨著整合胰島素給藥和監測系統的日益普及，以及主要監管機構的批准和積極的臨床應用，該地區的市場進一步增強。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

  • 產業生態系分析
  • 影響產業的因素
    • 促進因素
      • 糖尿病患者人數正在增加。
      • 糖尿病醫療費用增加
      • 人們對高科技產品的認知不斷提高
      • 優惠的還款政策
    • 產業潛在風險與挑戰
      • 新產品發布數量正在增加。
      • 先進設備高成本
    • 市場機遇
      • 將人工智慧和數據分析應用於糖尿病管理
      • 遠端患者監護（RPM）和遠端醫療的擴展
  • 成長潛力分析
  • 監理情勢
  • 技術展望
    • 最新科技趨勢
    • 新興技術
  • 價格趨勢分析
  • 未來市場趨勢
  • 專利分析
  • 波特的分析
  • PESTLE分析
  • 人工智慧和生成式人工智慧對市場的影響
  • 價值鏈分析
  • 投資與資金籌措分析
  • 消費者洞察

第4章 競爭情勢

  • 介紹
  • 企業市佔率分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 拉丁美洲
  • 主要進展
    • 重要合作夥伴關係和合作
    • 併購主要趨勢
    • 產品創新和新產品發布
    • 市場擴大策略
  • 競爭定位矩陣

第5章 市場規模及預測：依產品分類，2022-2035年

  • 裝置
    • 依設備類型
      • 智慧型血糖值儀
      • CGM
      • 智慧型胰島素幫浦和貼片
      • 智慧胰島素筆
    • 透過便攜性
      • 手持式
      • 穿戴式裝置
  • 服務
    • 遠端醫療和線上醫療諮詢服務
    • 遠端監控服務
    • 糖尿病教育、指導與支援服務
  • 軟體和應用程式
    • 數位糖尿病管理應用程式
    • 資料管理軟體和平台

第6章 市場規模與預測：依病患類型分類，2022-2035年

  • 1型
  • 類型 2

第7章 市場規模及預測：依最終用途分類，2022-2035年

  • 醫院
  • 首頁設定
  • 診斷中心和診所
  • 其他最終用戶

第8章 市場規模及預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 荷蘭
    • 西班牙
    • 義大利
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 南非
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥

第9章：公司簡介

  • Abbott Laboratories
  • Ascensia Diabetes Care Holdings AG
  • DarioHealth Corporation
  • Dexcom, Inc.
  • Emperra GmbH E-Health Technologies
  • F. Hoffmann-La Roche Ltd
  • Glooko Inc.
  • Insulet Corporation
  • Medtronic Plc
  • Novo Nordisk A/S
  • Pendiq
  • Senseonics
  • Tandem Diabetes Care, Inc.
  • Tidepool
  • Ypsomed Holding
簡介目錄
Product Code: 4903

The Global Digital Diabetes Management Market was valued at USD 20.2 billion in 2025 and is estimated to grow at a CAGR of 13.3% to reach USD 69.1 billion by 2035.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$20.2 Billion
Forecast Value$69.1 Billion
CAGR13.3%

Market growth is driven by a major shift in diabetes care delivery from intermittent clinical consultations toward continuous, technology-enabled monitoring supported by integrated digital ecosystems. Rising prevalence of diabetes, fueled by aging populations, sedentary lifestyles, and increasing obesity rates, is significantly expanding the patient base worldwide. At the same time, healthcare systems are facing a widening gap between patient demand and endocrinology workforce availability, which is accelerating the adoption of digital self-management tools. In several developing regions, limited access to specialist care is further increasing reliance on remote monitoring platforms and telehealth-enabled solutions. Growing healthcare expenditure related to diabetes is also contributing to the expansion of the addressable market for digital care technologies. Over the past few years, awareness and adoption of continuous glucose monitoring, connected insulin delivery systems, and integrated digital health platforms have increased substantially. This trend is supported by stronger clinical guidelines, expanding reimbursement frameworks, and increasing evidence demonstrating improved patient outcomes through digital intervention. Overall, the market is evolving rapidly as healthcare shifts toward connected, preventive, and data-driven diabetes management models.

The continuous glucose monitoring systems segment accounted for 53.4% share in 2025 and is projected to grow at a CAGR of 13.3% through 2035. This category remains the central pillar of the market due to its ability to provide real-time glucose tracking and continuous metabolic insights. Unlike traditional monitoring methods that offer intermittent readings, these systems deliver continuous data streams that support predictive alerts, pattern recognition, and improved insulin dosing decisions. Their clinical effectiveness in improving glycemic control and reducing complications continues to drive strong adoption across patient populations.

The hospitals segment generated 62.9% of the global digital diabetes management market revenue in 2025 and are projected to register a CAGR of 13.7% through the forecast period, representing the fastest-growing end-use segment. Growth is primarily supported by increasing investments in continuous glucose monitoring (CGM)-enabled inpatient care, wider implementation of automated insulin delivery (AID) technologies within specialized diabetes treatment departments, and growing adoption of enterprise-level data management platforms for clinical analytics, patient population monitoring, and reporting functions. The use of CGM systems in hospital environments has gained significant momentum as clinical studies continue to demonstrate improved glucose management outcomes across inpatient care settings.

North America Digital Diabetes Management Market accounted for 33.4% share in 2025 and is projected to grow at a CAGR of 13.1% through 2035. The region remains the most advanced and commercially developed market, supported by strong healthcare infrastructure, high adoption of digital health technologies, and favorable reimbursement frameworks. Canada is also experiencing steady growth, with expanding public healthcare coverage for advanced glucose monitoring solutions across major provinces. The region's market is further strengthened by widespread availability of integrated insulin delivery and monitoring systems, supported by leading regulatory approvals and strong clinical adoption.

Key companies operating in the Global Digital Diabetes Management Market include Dexcom, Inc., Medtronic Plc, Insulet Corporation, Abbott Laboratories, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, Glooko Inc., Senseonics, DarioHealth Corporation, Emperra GmbH E-Health Technologies, Ypsomed Holding, and Pendiq. Companies in the digital diabetes management market are focusing on strengthening their position through continuous technological innovation, ecosystem integration, and expansion of connected care platforms. A major strategy involves developing advanced continuous glucose monitoring systems and automated insulin delivery solutions with improved accuracy, real-time analytics, and predictive capabilities. Firms are increasingly investing in artificial intelligence and cloud-based platforms to enable seamless data sharing between patients and healthcare providers. Strategic partnerships with hospitals, insurers, and telehealth providers are helping expand adoption and improve reimbursement access. Companies are also focusing on interoperability between devices and software platforms to enhance user experience and clinical efficiency. Geographic expansion into emerging markets is being prioritized to capture growing patient populations with limited access to specialist care.

Table of Contents

Chapter 1. Methodology & Scope

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation for any one approach
  • 1.7 Market estimates & forecasts parameters
  • 1.8 Forecast model
    • 1.8.1 Quantified market impact analysis
      • 1.8.1.1 Mathematical impact of growth parameters on forecast
  • 1.9 Research transparency addendum
    • 1.9.1 Source attribution framework
    • 1.9.2 Quality assurance metrics
    • 1.9.3 Our commitment to trust
  • 1.10 Market definitions

Chapter 2. Executive Summary

  • 2.1 Industry synopsis, 2022 - 2035
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Patient Type trends
    • 2.1.4 End use trends
    • 2.1.5 Regional trends

Chapter 3. Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising number of people suffering from diabetes.
      • 3.2.1.2 Rising healthcare expenditure towards diabetes.
      • 3.2.1.3 Growing awareness about technologically advanced products.
      • 3.2.1.4 Favorable reimbursement policies.
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Rising number of product launches.
      • 3.2.2.2 High cost of advanced devices.
    • 3.2.3 Market opportunities
      • 3.2.3.1 Integration of AI and data analytics in diabetes management
      • 3.2.3.2 Expansion of remote patient monitoring (RPM) and telehealth
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape (Driven by primary research)
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 MEA
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Pricing trend analysis (Driven by primary research)
  • 3.7 Future market trends
  • 3.8 Patent analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis
  • 3.11 Impact of AI and Generative AI on the market (Driven by primary research)
  • 3.12 Value chain analysis (Driven by primary research)
  • 3.13 Investment & funding analysis (Driven by primary research)
  • 3.14 Consumer insights (Driven by primary research)

Chapter 4. Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis, by region, 2025
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
    • 4.2.4 Middle East & Africa
    • 4.2.5 Latin America
  • 4.3 Key developments
    • 4.3.1 Key partnerships & collaborations
    • 4.3.2 Major M&A activities
    • 4.3.3 Product innovations & launches
    • 4.3.4 Market expansion strategies
  • 4.4 Competitive positioning matrix

Chapter 5. Market Size and Forecast, By Product, 2022 - 2035 (USD Million)

  • 5.1 Key trends
  • 5.2 Devices
    • 5.2.1 By Device Type
      • 5.2.1.1 Smart blood glucose meters
      • 5.2.1.2 CGM
      • 5.2.1.3 Smart insulin pumps & patches
      • 5.2.1.4 Smart insulin pens
    • 5.2.2 By portability
      • 5.2.2.1 Handheld
      • 5.2.2.2 Wearable
  • 5.3 Services
    • 5.3.1 Telemedicine & virtual consultation services
    • 5.3.2 Remote monitoring services
    • 5.3.3 Diabetes education, coaching & support services
  • 5.4 Software and Apps
    • 5.4.1 Digital diabetes management apps
    • 5.4.2 Data management software & platforms

Chapter 6. Market Size and Forecast, By Patient type, 2022 - 2035 (USD Million)

  • 6.1 Key trends
  • 6.2 Type 1
  • 6.3 Type 2

Chapter 7. Market Size and Forecast, By End Use, 2022 - 2035 (USD Million)

  • 7.1 Key trends
  • 7.2 Hospital
  • 7.3 Home settings
  • 7.4 Diagnostic centers & clinics
  • 7.5 Other end users

Chapter 8. Market Size and Forecast, By Region, 2022 - 2035 (USD Million)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 France
    • 8.3.3 UK
    • 8.3.4 Netherlands
    • 8.3.5 Spain
    • 8.3.6 Italy
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 India
    • 8.4.5 Australia
  • 8.5 Middle East & Africa
    • 8.5.1 Saudi Arabia
    • 8.5.2 UAE
    • 8.5.3 South Africa
  • 8.6 Latin America
    • 8.6.1 Brazil
    • 8.6.2 Argentina
    • 8.6.3 Mexico

Chapter 9. Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Ascensia Diabetes Care Holdings AG
  • 9.3 DarioHealth Corporation
  • 9.4 Dexcom, Inc.
  • 9.5 Emperra GmbH E-Health Technologies
  • 9.6 F. Hoffmann-La Roche Ltd
  • 9.7 Glooko Inc.
  • 9.8 Insulet Corporation
  • 9.9 Medtronic Plc
  • 9.10 Novo Nordisk A/S
  • 9.11 Pendiq
  • 9.12 Senseonics
  • 9.13 Tandem Diabetes Care, Inc.
  • 9.14 Tidepool
  • 9.15 Ypsomed Holding